Presento una secuencia de textos que explican la evolución de importantes actores del entramado biotecnologico europeo desde el EMBO, al EMBL, EBI y EMBLEM.
The origins of EMBO date back to 1963, when a group of leading European biologists gathered in Ravello, Italy. They came together to discuss proposals by John Kendrew and Conrad Waddington to establish an organization and laboratory for cooperation in molecular biology. Both proposals were endorsed and in July 1964, the European Molecular Biology Organization (EMBO) was officially born.
The Ravello meeting laid down two initial goals for EMBO – the creation of a central laboratory and the establishment of networking activities to enhance interactions between scientists across Europe. To pursue these goals, two committees were set up. The efforts of the Laboratory Committee led to the establishment of the European Molecular Biology Laboratory (EMBL).
EMBL is an intergovernmental organisation established in 1974 by ten founding countries: Austria, Denmark, France, Germany, Israel, Italy, the Netherlands, Sweden, Switzerland and the United Kingdom. Member states make a contribution to EMBL’s programmes, receive access to all services and programmes and are responsible for all important decisions about the organisation and its activities taken in the EMBL Council. Member states are represented in the EMBL Council by up to two delegates.
Subsequently, EMBL was joined by Finland (1984), Greece (1984), Norway (1985), Spain (1986), Belgium (1990), Portugal (1998), Ireland (2003), Iceland (2005), Croatia (2006), Luxembourg (2007), the Czech Republic (2014), Malta (2016), Hungary (2017) and Slovakia (2018) as member states.
El peso de la secuenciación genómica y el destacado papel del Sanger Institute llevaron a trasladar a Gran Bretaña la instalación del EBI.
The roots of the EMBL-EBI lie in the EMBL Nucleotide Sequence Data Library (now known as EMBL-Bank), which was established in 1980 at the EMBL laboratories in Heidelberg, Germany and was the world's first nucleotide sequence database. The original goal was to establish a central computer database of DNA sequences, to supplement sequences submitted to journals. What began as a modest task of abstracting information from literature soon became a major database activity with direct electronic submissions of data and the need for highly skilled informatics staff. The task grew in scale with the start of the genome projects, and grew in visibility as the data became relevant to research in the commercial sector. It soon became apparent that the EMBL Nucleotide Sequence Data Library needed better financial security to ensure its long-term viability and to cope with the sheer scale of the task. (https://en.wikipedia.org/wiki/European_Bioinformatics_Institute)
We provide freely available data and bioinformatics services to all facets of the scientific community.: Tools & Data Resources, 109 y 61 servicios respectivamente.
We contribute to the advancement of biology through basic investigator-driven research
We provide advanced bioinformatics training to scientists at all levels
We help disseminate cutting-edge technologies to industry
We support, as an ELIXIR node, the coordination of biological data provision throughout Europe
Una pata importante es el instrumento de monetización de lo descubierto ó inventado, de ésto se encarga el EMBLEM
EMBLEM,(EMBL Enterprise Management Technology Transfer GmbH) founded in 1999, is the wholly owned subsidiary and exclusive technology and knowledge transfer partner of the European Molecular Biology Laboratory (EMBL). Based at the EMBL headquarters in Heidelberg (Germany), we are responsible for identifying, protecting and commercializing intellectual property and associated technologies and materials developed in the EMBL-world including the outstations Hinxton (U.K.), Hamburg (Germany), Grenoble (France) and Monterotondo (Italy).
No he visto ningún comentario sobre la posible influencia del Brexit en este conjunto de organizaciones de base intergubernamental, y aunque ésto quiere ser un blog de Genética, creo que la aplicación de la salida de Gran Bretaña de estas organizaciones sería malo para todos los intervinientes, muestra de que el Brexit es un enorme error, pero cada uno es libre de pegarse los tiros al pié que quiera.